
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
Keywords: AE; Adverse Event; α-MSH; alpha-Melanocyte Stimulating Hormone; ADC; Antibody-Drug Conjugate; ASPS; Alveolar Soft Part Sarcoma; ASPSCR1; Alveolar Soft Part Sarcoma Chromosome Region Candidate 1; BMP-2; Bone Morphogenetic Protein-2; BRK; Breast Tumor Kina